Updated statement on EU referendum from the British Pharmacopoeia
Following the result of the referendum on the UK’s membership of the European Union, the focus of the British Pharmacopoeia continues to be on our public health role as part of the Medicines and Healthcare Products Regulatory Agency. We continue to work to the highest levels of excellence and quality, working with and supporting our customers, partners and stakeholders to protect health and improve lives.
We continue to play a full and active role with all of our international stakeholders including the European Pharmacopoeia, part of the European Directorate for the Quality of Medicines and HealthCare under the Council of Europe. We continue to incorporate the contents of the European Pharmacopoeia including in-year updates.
We will consider the implications of any change to the UK’s relationship with the EU for the work of the British Pharmacopoeia. We continue to make a major contribution globally to improving public health through the development of authoritative quality standards for medicines, underpinned by science and research.
Read the full statement MHRA and making a success of Brexit.